Hemophilia A

New England Journal of Medicine

Volumn 330, Issue 1, 1994, Pages 38-47

  Hoyer, Leon W ^a  

^a HOLLAND LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9A; CALCIUM; DESMOPRESSIN; PHOSPHOLIPID; VON WILLEBRAND FACTOR;

BLOOD COMPONENT THERAPY; CLINICAL FEATURE; DOSE RESPONSE; DRUG EFFECT; GENETIC COUNSELING; HEMOPHILIA A; HEMOPHILIA B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW; VIRUS TRANSMISSION; VON WILLEBRAND DISEASE; X CHROMOSOME;

FACTOR VIII; HEMOPHILIA A; HUMAN; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028078717     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199401063300108     Document Type: Review

References (140)

1. Levine PH. Clinical manifestations and therapy of hemophilias A and B. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice. 2nd ed. Philadelphia: J.B. Lippincott, 1987:97-111.
2. Prevention and control of haemophilia: memorandum from a joint WHO/ WFH meeting (World Federation of Haemophilia). Bull World Health Organ 1991; 69: 17-26 [Erratum, Bull World Health Organ 1991;69:following 507.]
3. Rosendaal FR, Smit C, Briet E Hemophilia treatment in historical perspective: a review of medical and social developments. Ann Hematol 1991; 62: 5-15
4. Otto JC An account of an hemorrhagic disposition existing in certain families. Med Repos 1803; 6: 1-4
5. Ingram GIC The history of haemophilia. J Clin Pathol 1976; 29: 469-479
6. White GC II, Shoemaker CB Factor VIII gene and hemophilia A. Blood 1989; 73: 1-12
7. Bloom AL. Inherited disorders of blood coagulation. In: Bloom AL, Thomas DP, eds. Haemostasis and thrombosis. 2nd ed. Edinburgh, Scotland: Churchill Livingstone, 1987:393-436.
8. Roberts HR Molecular biology of hemophilia B. Thromb Haemost 1993; 70: 1-9
9. Giannelli F, Green PM, High KA, Haemophilia B: database of point mutations and short additions and deletions -- second edition. Nucleic Acids Res 1991; 19: Suppl: 2193-2219
10. Kane WH, Davie EW Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 1988; 71: 539-555
11. Foster PA, Zimmerman TS Factor VIII structure and function. Blood Rev 1989; 3: 180-191
12. Hoyer LW The factor VIII complex: structure and function. Blood 1981; 58: 1-13
13. Fulcher CA, Zimmerman TS Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody. Proc Natl Acad Sci U S A 1982; 79: 1648-1652
14. Kaufman RJ, Wasley LC, Davies MV, Wise RJ, Israel DI, Dorner AJ Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol 1989; 9: 1233-1242
15. Weiss HJ, Sussman II, Hoyer LW Stabilization of factor VIII in plasma by the von Willebrand factor: studies on post-transfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 1977; 60: 390-404
16. van Dieijen G, Tans G, Rosing J, Hemker HC The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-3442
17. Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1-16
18. Nesheim M, Pittman DD, Giles AR, The effect of plasma von Willebrand factor on the binding of human factor VIII to thrombin-activated human platelets. J Biol Chem 1991; 266: 17815-17820
19. Tuddenham EG von Willebrand factor and its disorders: an overview of recent molecular studies. Blood Rev 1989; 3: 251-262
20. Handin RI, Wagner DD Molecular and cellular biology of von Willebrand factor. Prog Hemost Thromb 1989; 9: 233-259
21. Mosesson MW, Fass DN, Lollar P, Structural model of porcine factor VIII and factor VIIIa molecules based on scanning transmission electron microscope (STEM) images and STEM mass analysis. J Clin Invest 1990; 85: 1983-1990
22. Fay PJ, Smudzin TM Intersubunit fluorescence energy transfer in human factor VIII. J Biol Chem 1989; 264: 14005-14010
23. Lollar P The association of factor VIII with von Willebrand factor. Mayo Clin Proc 1991; 66: 524-534
24. Fay PJ, Smudzin TM Topography of the human factor VIII-von Willebrand factor complex. J Biol Chem 1990; 265: 6197-6202
25. Hill-Eubanks DC, Parker CG, Lollar P Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin. Proc Natl Acad Sci U S A 1989; 86: 6508-6512
26. Gitschier J, Wood WI, Goralka TM, Characterization of the human factor VIII gene. Nature 1984; 312: 326-330
27. Toole JJ, Knopf JL, Wozney JM, Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-347
28. Fowler WE, Fay PJ, Arvan DS, Marder VJ Electron microscopy of human factor V and factor VIII: correlation of morphology with domain structure and localization of factor V activation fragments. Proc Natl Acad Sci U S A 1990; 87: 7648-7652
29. Vehar GA, Keyt B, Eaton D, Structure of human factor VIII. Nature 1984; 312: 337-342
30. Bartles JR, Galvin NJ, Frazier WA Discoidin I-membrane interactions. II. Discoidin I binds to and agglutinates negatively charged phospholipid vesicles. Biochim Biophys Acta 1982; 687: 129-136
31. Poole S, Firtel RA, Lamar E, Rowekamp W Sequence and expression of the discoidin I gene family in Dictyostelium discoideum. J Mol Biol 1981; 153: 273-289
32. Burke RL, Pachl C, Quiroga M, The functional domains of coagulation factor VIII:C. J Biol Chem 1986; 261: 12574-12578
33. Eaton DL, Wood WI, Eaton D, Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochemistry 1986; 25: 8343-8347
34. Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ A large region (approximately 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci U S A 1986; 83: 5939-5942
35. Eaton D, Rodriguez H, Vehar GA Proteolytic processing of human factor VIII: correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505-512
36. Rotblat F, O'Brien DP, O'Brien FJ, Goodall AH, Tuddenham EGD Purification of human factor VIII:C and its characterization by Western blotting using monoclonal antibodies. Biochemistry 1985; 24: 4294-4300
37. Pittman DD, Kaufman RJ Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII). Proc Natl Acad Sci U S A 1988; 85: 2429-2433
38. Arai M, Inaba H, Higuchi M, Direct characterization of factor VIII in plasma: detection of a mutation altering a thrombin cleavage site (arginine-372-to-histidine). Proc Natl Acad Sci U S A 1989; 86: 4277-4281
39. Aly AM, Hoyer LW Factor VIII-East Hartford (arginine 1689 to cysteine) has procoagulant activity when separated from von Willebrand factor. J Clin Invest 1992; 89: 1382-1387
40. Lollar P, Parker CG Subunit structure of thrombin-activated porcine factor VIII. Biochemistry 1989; 28: 666-674
41. Pittman DD, Millenson M, Marquette K, Bauer K, Kaufman RJ A2 domain of human recombinant-derived factor VIII is required for procoagulant activity but not for thrombin cleavage. Blood 1992; 79: 389-397
42. Fay PJ, Haidaris PJ, Smudzin TM Human factor VIIIa subunit structure: reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem 1991; 266: 8957-8962
43. Hill-Eubanks DC, Lollar P von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain. J Biol Chem 1990; 265: 17854-17858
44. Osterud B, Rapaport SI Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci U S A 1977; 74: 5260-5264
45. Broze GJ Jr The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 1992; 29: 159-169
46. Repke D, Gemmell CH, Guha A, Turitto VT, Broze GJ Jr, Nemerson Y Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor. Proc Natl Acad Sci U S A 1990; 87: 7623-7627
47. Rick ME, Hoyer LW Thrombin activation of factor VIII: the effect of inhibitors. Br J Haematol 1977; 36: 585-597
48. Hultin MB, Jesty J The activation and inactivation of human factor VIII by thrombin: effect of inhibitors of thrombin. Blood 1981; 54: 476-482
49. Fay PJ Subunit structure of thrombin-activated human Factor VIIIa. Biochim Biophys Acta 1988; 952: 181-190
50. Lollar P, Parker CG pH-dependent Denaturation of thrombin-activated porcine factor VIII. J Biol Chem 1990; 265: 1688-1692
51. Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood 1984; 63: 486-489
52. Walker FJ, Fay PJ Regulation of blood coagulation by the protein C system. FASEB J 1992; 6: 2561-2567
53. Fay PJ, Smudzin TM, Walker FJ Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa: identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem 1991; 266: 20139-20145
54. Antonarakis SE The molecular genetics of hemophilia A and B in man: factor VIII and factor IX deficiency. Adv Hum Genet 1988; 17: 27-59
55. Gitschier J. The molecular genetics of hemophilia A. In: Zimmerman TS, Ruggeri ZM, eds. Coagulation and bleeding disorders: the role of factor VIII and von Willebrand factor. New York: Marcel Dekker, 1989:23-46.
56. Tuddenham EGD, Cooper DN, Gitschier J, Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene. Nucleic Acids Res 1991; 19: 4821-4833
57. Youssoufian H, Kazazian HH Jr, Phillips DG, Recurrent mutations in haemophilia A give evidence for CpG mutation hotspots. Nature 1986; 324: 380-382
58. Higuchi M, Antonarakis SE, Kasch L, Molecular characterization of mild-to-moderate hemophilia A: detection of the mutation in 25 of 29 patients by denaturing gradient gel electrophoresis. Proc Natl Acad Sci U S A 1991; 88: 8307-8311
59. Kogan S, Gitschier J Mutations and a polymorphism in the factor VIII gene discovered by denaturing gradient gel electrophoresis. Proc Natl Acad Sci U S A 1990; 87: 2092-2096
60. Traystman MD, Higuchi M, Kasper CK, Antonarakis SE, Kazazian HH Jr Use of denaturing gradient gel electrophoresis to detect point mutations in the factor VIII gene. Genomics 1990; 6: 293-301
61. Naylor JA, Green PM, Montandon AJ, Rizza CR, Giannelli F Detection of three novel mutations in two haemophilia A patients by rapid screening of whole essential region of factor VIII gene. Lancet 1991; 337: 635-639
62. Naylor JA, Green PM, Rizza CR, Giannelli F Factor VIII gene explains all cases of haemophilia A. Lancet 1992; 340: 1066-1067
63. Higuchi M, Kazazian HH Jr, Kasch L, Molecular characterization of severe hemophilia A suggests that about half the mutations are not within the coding regions and splice junctions of the factor VIII gene. Proc Natl Acad Sci U S A 1991; 88: 7405-7409
64. Lakich D, Kazazian HH, Antonarakis SE, Gitschier J Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nature Genet 1993; 5: 236-241
65. Kitchens CS Occult hemophilia. Johns Hopkins Med J 1980; 146: 255-259
66. Heath AB, Barrowcliffe TW Standardisation of factor VIII-V: calibration of the 2nd International Standard for Factor VIII and von Willebrand Factor activities in plasma. Thromb Haemost 1992; 68: 155-159
67. Ruggeri ZM Structure and function of von Willebrand factor: relationship to von Willebrand's disease. Mayo Clin Proc 1991; 66: 847-861
68. Weiss HJ, Hoyer LW, Rickles FR, Varma A, Rogers J Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation: relationship to factor VIII procoagulant activity and antigen content. J Clin Invest 1973; 52: 2708-2716
69. Nishino M, Girma J-P, Rothschild C, Fressinaud E, Meyer D New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989; 74: 1591-1599
70. Mazurier C, Dieval J, Jorieux S, Delobel J, Goudemand M A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF: characterization of abnormal vWF/FVIII interaction. Blood 1990; 75: 20-26
71. Gaucher C, Jorieux S, Mercier B, Oufkir D, Mazurier C The “Normandy” variant of von Willebrand disease: characterization of a point mutation in the von Willebrand factor gene. Blood 1991; 77: 1937-1941
72. Hoyer LW Immunochemical properties of factor VIII and factor IX inhibitors. Blood Coagul Fibrinolysis 1991; 2: 11-15
73. Larsson SA Life expectancy of Swedish haemophiliacs, 1831-1980. Br J Haematol 1985; 59: 593-602
74. Smit C, Rosendaal FR, Varekamp I, Physical condition, longevity, and social performance of Dutch haemophiliacs, 1972-85. BMJ 1989; 298: 235-238
75. Jones PK, Ratnoff OD The changing prognosis of classic hemophilia (factor VIII “deficiency”). Ann Intern Med 1991; 114: 641-648
76. McGrady GA, Jason JM, Evatt BL The course of the epidemic of acquired immunodeficiency syndrome in the United States hemophilia population. Am J Epidemiol 1987; 126: 25-30
77. Stehr-Green JK, Holman RC, Jason JM, Evatt BL Hemophilia-associated AIDS in the United States, 1981 to September 1987. Am J Public Health 1988; 78: 439-442
78. Goedert JJ, Kessler CM, Aledort LM, A prospective study of human immunodeficiency virus type I infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989; 321: 1141-1148
79. Holman RC, Rhodes PH, Chorba TL, Evatt BL Survival of hemophilic males with acquired immunodeficiency syndrome with and without risk factors for AIDS other than hemophilia. Am J Hematol 1992; 39: 275-282
80. Jackson JB, Sannerud KJ, Hopsicker JS, Hemophiliacs with HIV antibody are actively infected. JAMA 1988; 260: 2236-2239
81. Ragni MV, Tegtmeier GE, Levy JA, AIDS retrovirus antibodies in hemophiliacs treated with factor VIII or factor IX concentrates, cryoprecipitate, or fresh frozen plasma: prevalence, seroconversion rate, and clinical correlations. Blood 1986; 67: 592-595
82. Eyster ME, Goedert JJ, Sarngadharan MG, Weiss SH, Gallo RC, Blattner WA Development and early natural history of HTLV-III antibodies in persons with hemophilia. JAMA 1985; 253: 2219-2223
83. Goedert JJ, Sarngadharan MG, Eyster ME, Antibodies reactive with human T cell leukemia viruses in the serum of hemophiliacs receiving factor VIII concentrate. Blood 1985; 65: 492-495
84. Pool JG, Hershgold EJ, Pappenhagen AR High-potency antihaemophilic factor concentrate prepared from cryoglobulin in precipitate. Nature 1964; 203: 312-312
85. Bloom AL Progress in the clinical management of haemophilia. Thromb Haemost 1991; 66: 166-177
86. Brettler DB, Levine PH Factor concentrates for treatment of hemophilia: which one to choose? Blood 1989; 73: 2067-2073
87. Pierce GF, Lusher JM, Brownstein AP, Goldsmith JC, Kessler CM The use of purified clotting factor concentrates in hemophilia: influence of viral safety, cost, and supply on therapy. JAMA 1989; 261: 3434-3438
88. Addiego JE Jr, Gomperts E, Liu S-L, Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography. Thromb Haemost 1992; 67: 19-27
89. Lusher JM, Salzman PM Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates: the Monoclate Study Group. Semin Hematol 1990; 27: Suppl 2: 1-7
90. McMillan CW, Webster WP, Roberts HR, Blythe WB Continuous intravenous infusion of factor VIII in classic haemophilia. Br J Haematol 1970; 18: 659-667
91. Bona RD, Weinstein RA, Weisman SJ, Bartolomeo A, Rickles FR The use of continuous infusion of factor concentrates in the treatment of hemophilia. Am J Hematol 1989; 32: 8-13
92. Aledort LM, Levine PH, Hilgartner M, A study of liver biopsies and liver disease among hemophiliacs. Blood 1985; 66: 367-372
93. Gomperts E, Lundblad R, Adamson R The manufacturing process of recombinant factor VIII, recombinate. Transfus Med Rev 1992; 6: 247-251
94. Boedeker BGD The manufacturing of the recombinant factor VIII, Kogenate. Transfus Med Rev 1992; 6: 256-260
95. White GC, McMillan CW, Kingdon HS, Shoemaker CB Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. N Engl J Med 1989; 320: 166-170
96. Growe GH, Poon M-C, Scarth I International Symposium on Recombinant Factor VIII: report of the proceedings. Transfus Med Rev 1992; 6: 137-145
97. Bray GL Current status of clinical studies of recombinant factor VIII (Recombinate) in patients with hemophilia A. Transfus Med Rev 1992; 6: 252-255
98. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS, Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A: safety, efficacy, and development of inhibitors. N Engl J Med 1993; 328: 453-459
99. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32
100. de la Fuente B, Casper CK, Rickles FR, Hoyer LW Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin. Ann Intern Med 1985; 103: 6-14
101. Mannucci PM Desmopressin: a nontransfusional hemostatic agent. Annu Rev Med 1990; 41: 55-64
102. Lethagen S, Harris AS, Nilsson IM Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type I. Blut 1990; 60: 187-191
103. Kasper CK Treatment of factor VIII inhibitors. Prog Hemost Thromb 1989; 9: 57-86
104. Bloom AL. The treatment of factor VIII inhibitors. In: Verstraete M, Vermylen J, Lijnen R, Arnout J, eds. Thrombosis and haemostasis, 1987. Leuven, Belgium: Leuven University Press, 1987:447-71.
105. Rasi V, Ikkala E Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 1990; 76: 369-371
106. Sultan Y Prevalence of inhibitors in a population of 3435 hemophilia patients in France: French Hemophilia Study Group. Thromb Haemost 1992; 67: 600-602
107. Ehrenforth S, Kreuz W, Scharrer I, Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598
108. Aly AM, Aledort LM, Lee TD, Hoyer LW Histocompatibility antigen patterns in haemophilic patients with factor VIII antibodies. Br J Haematol 1990; 76: 238-241
109. Kasper CK, Aledort LM, Aronson D, Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612-612
110. Allain J-P, Frommel D Antibodies to factor VIII. V. Patterns of immune response to factor VIII in hemophilia A. Blood 1976; 47: 973-982
111. Brettler DB, Forsberg AD, Levine PH, The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII: a multicenter US experience. Arch Intern Med 1989; 149: 1381-1385
112. Hay CRM An update on experience with Hyate:C with regard to antibody development. Blood Coagul Fibrinolysis 1991; 2: 31-35
113. Hay CRM, Bolton-Maggs P. Porcine factor VIII:C in the management of patients with factor VIII inhibitors. Transfus Med Rev 1991;5:145-51. [Corrected and republished article, Transfus Med Rev 1991;5:293-9.]
114. Lusher JM, Shapiro SS, Palascak JE, Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. N Engl J Med 1980; 303: 421-425
115. Lusher JM, Blatt PM, Penner JA, Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood 1983; 62: 1135-1138
116. Sjamsoedin LJM, Heijnen L, Mauser-Bunschoten EP, The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII: a double-blind clinical trial. N Engl J Med 1981; 305: 717-721
117. Hedner U, Glazer S, Pingel K, Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193-1193
118. Slocombe GW, Newland AC, Colvin MP, Colvin BT The role of intensive plasma exchange in the prevention and management of haemorrhage in patients with inhibitors to factor VIII. Br J Haematol 1981; 47: 577-585
119. Uehlinger J, Button GR, McCarthy J, Forster A, Watt R, Aledort LM Immunoadsorption for coagulation factor inhibitors. Transfusion 1991; 31: 265-269
120. Nilsson IM, Jonsson S, Sundqvist S-B, Ahlberg A, Bergentz S-E A procedure for removing high titer antibodies by extracorporeal protein-A-sepharose adsorption in hemophilia: substitution therapy and surgery in a patient with hemophilia B and antibodies. Blood 1981; 58: 38-44
121. Green D Cytotoxic suppression of acquired factor VIII:C inhibitors. Am J Med 1991; 91: Suppl 5A: 5A-14S
122. Sultan Y, Kazatchkine MD, Nydegger U, Rossi F, Dietrich G, Algiman M Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII:C inhibitors. Am J Med 1991; 91: Suppl 5A: 5A-35S
123. Nilsson IM, Berntorp E, Zettervall O Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318: 947-950
124. Hay CRM, Laurian Y, Verroust F, Preston FE, Kernoff PBA Induction of immune tolerance in patients with hemophilia A and inhibitors treated with porcine VIIIC by home therapy. Blood 1990; 76: 882-886
125. Zimmerman TS, Ratnoff OD, Littell AS Detection of carriers of classic hemophilia using an immunologic assay for antihemophilic factor (factor VIII). J Clin Invest 1971; 50: 255-258
126. Graham JB Genetic counseling in classic hemophilia A. N Engl J Med 1977; 296: 996-998
127. Klein HG, Aledort LM, Bouma BN, Hoyer LW, Zimmerman TS, DeMets DL A co-operative study for the detection of the carrier state of classic hemophilia. N Engl J Med 1977; 296: 959-962
128. Varekamp I, Suurmeijer TPBM, Brocker-Vriends AHJT, Carrier testing and prenatal diagnosis for hemophilia: experiences and attitudes of 549 potential and obligate carriers. Am J Med Genet 1990; 37: 147-154
129. Gitschier J, Drayna D, Tuddenham EGD, White RL, Lawn RM Genetic mapping and diagnosis of haemophilia A achieved through a BclI polymorphism in the factor VIII gene. Nature 1985; 314: 738-740
130. Peake I Registry of DNA polymorphisms within or close to the human factor VIII and factor IX genes: for the Factor VIII/IX Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1992; 67: 277-280
131. Sadler JE Recombinant DNA methods in hemophilia A: carrier detection and prenatal diagnosis. Semin Thromb Hemost 1990; 16: 341-347
132. Lalloz MRA, McVey JH, Pattinson JK, Tuddenham EGD Haemophilia A diagnosis by analysis of a hypervariable dinucleotide repeat within the factor VIII gene. Lancet 1991; 338: 207-211
133. Firshein SI, Hoyer LW, Lazarchick J, Prenatal diagnosis of classic hemophilia. N Engl J Med 1979; 300: 937-941
134. Hoyer LW, Carta CA, Golbus MS, Hobbins JC, Mahoney MJ Prenatal diagnosis of classic hemophilia (hemophilia A) by immunoradiometric assays. Blood 1985; 65: 1312-1317
135. Gitschier J, Lawn RM, Rotblat F, Goldman E, Tuddenham EGD Antenatal diagnosis and carrier detection of haemophilia A using factor VIII gene probe. Lancet 1985; 1: 1093-1094
136. Tedgard U, Ljung R, McNeil T, Tedgard E, Schwartz M How do carriers of hemophilia experience prenatal diagnosis (PND)? Carriers' immediate and later reactions to amniocentesis and fetal blood sampling. Acta Paediatr Scand 1989; 78: 692-700
137. Miller CH, Hilgartner MW, Aledort LM Reproductive choices in hemophilic men and carriers. Am J Med Genet 1987; 26: 591-598
138. Bontempo FA, Lewis JH, Gorenc TJ, Liver transplantation in hemophilia A. Blood 1987; 69: 1721-1724
139. Israel DI, Kaufman RJ Retroviral-mediated transfer and amplification of a functional human factor VIII gene. Blood 1990; 75: 1074-1080
140. Thompson AR Status of gene transfer for hemophilia A and B. Thromb Haemost 1991; 66: 119-122